The latest price target for Apogee Therapeutics (NASDAQ:APGE) was reported by Guggenheim on December 12, 2024. The analyst firm set a price target for $0.00 expecting APGE to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Apogee Therapeutics (NASDAQ:APGE) was provided by Guggenheim, and Apogee Therapeutics reiterated their buy rating.

There is no last upgrade for Apogee Therapeutics

There is no last downgrade for Apogee Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a reiterated with a price target of $0.00 to $0.00. The current price Apogee Therapeutics (APGE) is trading at is $47.71, which is out of the analyst’s predicted range.